πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,265 results for β€œGan” Clear

  1. Ensartinib

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  2. Envafolimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  3. Envafolimab

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. Envafolimab Injection

    The First People's Hospital of Lianyungang

    Gastrointestinal Neoplasms

    phase 2 small molecule active

    1 trial

  5. Etoposide

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  6. Experimental

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer (LARC)

    phase 2 small molecule active

    1 trial

  7. Experimental: tislelizumab+anlotinib

    The First People's Hospital of Lianyungang

    Thymic Carcinoma

    phase 2 small molecule active

    1 trial

  8. FCN-437c+Fulvestrant

    The First People's Hospital of Lianyungang

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  9. FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  10. First-line Cohort

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  11. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

  12. Fluoxetine (drug)

    The First People's Hospital of Lianyungang

    Hepatobiliary Malignancy

    phase 2 small molecule active

    1 trial

  13. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. GC4419 (avasopasem manganese)

    Galera Therapeutics

    Esophagitis

    phase 2 small molecule terminated

    1 trial

  15. GVA + HDAC Consolidation & Gilteritinib Maintenance

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  16. GZR102

    Gan & Lee Pharmaceuticals.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  17. Ganoderma lucidum spore

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  18. Gatifloxacin 0.3% ophthalmic solution

    Allergan Pharmaceuticals International Limited

    Acute Bacterial Corneal Ulcers

    phase 2 small molecule completed

    1 trial

  19. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  20. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-SchΓΆnlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  21. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  22. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  23. HB0043

    The First People's Hospital of Lianyungang

    Acne Vulgaris

    phase 2 small molecule active

    1 trial

  24. HUMSCs combined with bovine type I collagen

    The First People's Hospital of Lianyungang

    Burn Wounds

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources